Selzentry (Maraviroc, Celsentri)
| Brand Name: |
Selzentry |
| Generic Name: |
Maraviroc, MVC |
| Adult Single Dose*: |
One 300 mg tablet twice daily |
| Food & Liquid Restrictions: |
None. |
| Drug Class: |
Entry Inhibitor |
|
|
|
READ FIRST:
- An Overview of Selzentry (Maraviroc, Celsentri) (June 3, 2010)
From AIDSinfo
- A Revolutionary New Way to Fight HIV/AIDS: CCR5 Inhibitors (September 2008)
Find out more about Selzentry in this special report.
From The Body
- Maraviroc (Selzentry, Celsentri) (June 14, 2011)
To read PDF, click here.
From AIDS InfoNet
- A New Way to Fight HIV: CCR5 Inhibitors (April 30, 2008)
An interview with David Hardy, M.D.
From The Body
- Selzentry (March/April 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- The Basics on Maraviroc: An Interview With Joel Gallant, M.D., M.P.H. (August 6, 2007)
From The Body
The Basics
- Characteristics of Integrase Inhibitor, Fusion Inhibitor and CCR5 Antagonist (PDF) (January 10, 2011)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo
- Selzentry (Maraviroc, Celsentri) Official Prescribing Information and Drug Warnings (PDF) (November 2009)
From Pfizer, Inc.
- Selzentry (Maraviroc) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- FDA Approves Pfizer's Antiretroviral Maraviroc (August 7, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Approval of Maraviroc (August 6, 2007)
From U.S. Food and Drug Administration
- CCR5: A Genetic Mistake Makes Good (March 2004)
[Archived Article]
From amfAR, The Foundation for AIDS Research
|
Advertisement
|
Email
Glossary
